Joanne M. Munck

1.0k total citations
19 papers, 556 citations indexed

About

Joanne M. Munck is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Joanne M. Munck has authored 19 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Joanne M. Munck's work include Melanoma and MAPK Pathways (6 papers), DNA Repair Mechanisms (3 papers) and Ubiquitin and proteasome pathways (3 papers). Joanne M. Munck is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), DNA Repair Mechanisms (3 papers) and Ubiquitin and proteasome pathways (3 papers). Joanne M. Munck collaborates with scholars based in United Kingdom, United States and Spain. Joanne M. Munck's co-authors include Nicola J. Curtin, David R. Newell, Alison M. Motley, Ewald H. Hettema, Michele Tavecchio, Céline Cano, John F. Lyons, James M. Nuttall, Mohammad Azab and Tomoko Smyth and has published in prestigious journals such as The Journal of Cell Biology, Blood and Cancer Research.

In The Last Decade

Joanne M. Munck

19 papers receiving 545 citations

Peers

Joanne M. Munck
Janice M. Mehnert United States
Yvonne Li Canada
Margaret Soucheray United States
Kenna Shirasuna Japan
Chu Myong Seong South Korea
Steve W. Elmore United States
Silvia Licciulli Italy
Hélène Malka-Mahieu France
Robert H. Sinnamon United States
Luana D’Artista Italy
Janice M. Mehnert United States
Joanne M. Munck
Citations per year, relative to Joanne M. Munck Joanne M. Munck (= 1×) peers Janice M. Mehnert

Countries citing papers authored by Joanne M. Munck

Since Specialization
Citations

This map shows the geographic impact of Joanne M. Munck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne M. Munck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne M. Munck more than expected).

Fields of papers citing papers by Joanne M. Munck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne M. Munck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne M. Munck. The network helps show where Joanne M. Munck may publish in the future.

Co-authorship network of co-authors of Joanne M. Munck

This figure shows the co-authorship network connecting the top 25 collaborators of Joanne M. Munck. A scholar is included among the top collaborators of Joanne M. Munck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne M. Munck. Joanne M. Munck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ang, J.E., S. Gaillard, Hsin‐An Chen, et al.. (2024). 791P Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway. Annals of Oncology. 35. S591–S591. 1 indexed citations
2.
Sharma, Priyanka, Natalia Baran, Qi Zhang, et al.. (2024). ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax. Blood. 144(Supplement 1). 2759–2759. 1 indexed citations
3.
Sharma, Priyanka, Sujan Piya, Natalia Baran, et al.. (2023). P460: ERK1/2 INHIBITION OVERCOMES RESSITANCE TO BCL2 INHIBITION IN ACUTE MYELOID LEUKEMIA BY IMPACT ON MITOCHONDRIAL DYNAMICS AND FUNCTION. HemaSphere. 7(S3). e08176db–e08176db. 1 indexed citations
4.
Sharma, Priyanka, Sujan Piya, Baozhen Ke, et al.. (2023). ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission. Blood. 142(Supplement 1). 412–412. 1 indexed citations
5.
Crawford, Nyree, Tamas Sessler, Christopher McCann, et al.. (2021). Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer. Molecular Cancer Therapeutics. 20(9). 1627–1639. 21 indexed citations
6.
Ferrari, Nicola, George A. Ward, Christina Gewinner, et al.. (2021). Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma. Blood Advances. 5(20). 4003–4016. 5 indexed citations
7.
Ferrari, Nicola, George A. Ward, Joanne M. Munck, et al.. (2020). Abstract 5542: ASTX660, a non-peptidomimetic antagonist of cIAP1/2 and XIAP, enhances immune mediated tumor killing and induction of immunogenic cell death. Cancer Research. 80(16_Supplement). 5542–5542. 1 indexed citations
8.
Hindley, Christopher J., Lynsey Fazal, Joanne M. Munck, et al.. (2020). Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models. Blood. 136(Supplement 1). 7–8. 1 indexed citations
9.
Kidger, Andrew M., Joanne M. Munck, Harpreet K. Saini, et al.. (2019). Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2. Molecular Cancer Therapeutics. 19(2). 525–539. 17 indexed citations
10.
Ward, George A., Edward J. Lewis, Jong Sook Ahn, et al.. (2018). ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Molecular Cancer Therapeutics. 17(7). 1381–1391. 53 indexed citations
11.
Musi, Elgilda, Grazia Ambrosini, Joanne M. Munck, & Gary K. Schwartz. (2018). Abstract 5784: A novel ERK inhibitor in the treatment of uveal melanoma. Cancer Research. 78(13_Supplement). 5784–5784. 1 indexed citations
12.
Fang, Fang, Joanne M. Munck, Jessica Tang, et al.. (2014). The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer. Clinical Cancer Research. 20(24). 6504–6516. 81 indexed citations
13.
Cornell, Liam, Joanne M. Munck, Clara Alsinet, et al.. (2014). DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research. 21(4). 925–933. 69 indexed citations
14.
Smyth, Tomoko, Kim H.T. Paraiso, Keisha Hearn, et al.. (2014). Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models. Molecular Cancer Therapeutics. 13(12). 2793–2804. 66 indexed citations
15.
Munck, Joanne M., et al.. (2013). Intra-ER sorting of the peroxisomal membrane protein Pex3 relies on its luminal domain. Biology Open. 2(8). 829–837. 31 indexed citations
16.
Munck, Joanne M., Michael A. Batey, Yan Zhao, et al.. (2012). Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K. Molecular Cancer Therapeutics. 11(8). 1789–1798. 99 indexed citations
17.
Cornell, Liam, Joanne M. Munck, Nicola J. Curtin, & Helen L. Reeves. (2012). PTU-042 DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo- and radio sensitivity in hepatocellular cancer cell lines. Gut. 61(Suppl 2). A201.1–A201. 1 indexed citations
18.
Tavecchio, Michele, Joanne M. Munck, Céline Cano, David R. Newell, & Nicola J. Curtin. (2011). Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemotherapy and Pharmacology. 69(1). 155–164. 53 indexed citations
19.
Munck, Joanne M., Alison M. Motley, James M. Nuttall, & Ewald H. Hettema. (2009). A dual function for Pex3p in peroxisome formation and inheritance. The Journal of Cell Biology. 187(4). 463–471. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janice M. Mehnert Breakdown of academic impact, for papers by Yvonne Li Breakdown of academic impact, for papers by Margaret Soucheray Breakdown of academic impact, for papers by Kenna Shirasuna Breakdown of academic impact, for papers by Chu Myong Seong Breakdown of academic impact, for papers by Steve W. Elmore Breakdown of academic impact, for papers by Silvia Licciulli Breakdown of academic impact, for papers by Hélène Malka-Mahieu Breakdown of academic impact, for papers by Robert H. Sinnamon Breakdown of academic impact, for papers by Luana D’Artista
Rankless by CCL
2026